WA-SPIE
11.1.2022 18:39:07 CET | Business Wire | Press release
The Awards Committee of SPIE, the international society for optics and photonics , today announced the recipients of its prestigious annual awards . Honoring transformative advancements in multiple areas — including medicine, astronomy, lithography, optical metrology, optical design, and community leadership — the Society's awards recognize technical accomplishments as well as committed service to SPIE and support of its organizational mission.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220110005942/en/
SPIE Gold Medal: Michael Berns
In recognition of his work in bioengineering research and his distinguished career that brought together engineers, physicists, biologists, and physicians to collaborate on ground-breaking discoveries and innovations.
SPIE President's Award: Tuan Vo-Dinh
In recognition of his outstanding and extensive role in SPIE conference leadership, in disparate technical areas, and for his mentorship of early investigators as well as peers.
SPIE Directors' Award: Julie Bentley
In recognition of her outstanding service to the Society in extraordinary ways, including authorship, course instruction, conference program leadership, committee membership, and service on the Board of Directors.
SPIE Mozi Award: Thomas W. Ebbesen
In recognition of his phenomenal contributions to the field of nano-optics, especially the extraordinary optical transmission through sub-wavelength hole arrays.
SPIE Britton Chance Award in Biomedical Optics: Bruce Tromberg
In recognition of his high-impact translational research and overall leadership in the development of biophotonic technologies for diagnostics and therapeutics.
SPIE Biophotonics Technology Innovator Award: Bert Müller
In recognition of his distinguished contributions to 2D and 3D imaging for the challenges of the 21st century, including cardiovascular and neurodegenerative diseases, bioinspired dental repair, and incontinence treatment.
SPIE Rudolf and Hilda Kingslake Award in Optical Design: Masato Shibuya
In recognition of his significant contributions to the development of optical design through the invention of phase-shift masks for photolithography, and for laying the foundations of imaging theory based on plane-wave expansions.
SPIE Harrison H. Barrett Award in Medical Imaging: Maryellen Giger
In recognition of her pioneering work in the fields of digital image formation, computer-aided diagnosis, radiomics, and radiogenomics.
SPIE Harold E. Edgerton Award in High-Speed Optics: Mona Jarrahi
In recognition of her pioneering contributions to plasmonic time-domain spectroscopy and imaging systems as well as their scientific and industrial applications.
SPIE Dennis Gabor Award in Diffractive Optics: Gabriel Popescu
In recognition of his groundbreaking contributions to holography and quantitative phase imaging for biomedical applications.
SPIE George W. Goddard Award in Space and Airborne Optics: Michelle Stephens
In recognition of her technical innovation, mentoring, and exceptional leadership in pursuit of space-based, fundamental measurements of the Earth and Sun, while reducing technological barriers and promoting standards for the advancement of space and airborne optics.
SPIE G. G. Stokes Award in Optical Polarization: Alex Vitkin
In recognition of his extensive contributions to tissue polarimetry, including advanced methodology developments for sensitive and robust Stokes and Mueller measurements; polarimetric computational and analytical platforms; and biomedical applications including cardiology, regenerative medicine, glucometry, and breast-cancer margin assessment.
SPIE Chandra S. Vikram Award in Optical Metrology: Jürgen Czarske
In recognition of his important contributions to computational laser metrology with paradigm changes in fluid dynamics, inspection, aerospace, communication, and biomedicine.
SPIE Frits Zernike Award for Microlithography: Harry J. Levinson
In recognition of his outstanding achievements contributing to our fundamental understanding of advanced lithography process control, especially in the concepts of Image-Log-Slope, Mask defect printability, and thin-film optics optimization.
SPIE Diversity Outreach Award: Qaisar Abbas Naqvi
In recognition of his inspirational attitude and dedication to students, helping transform the lives of women and men from traditionally under-recognized segments of society by supporting their pursuit of higher education and research in optics and related fields.
SPIE Maria Goeppert-Mayer Award in Photonics: Shin-Tson Wu
In recognition of his seminal contributions to display and photonic device technologies that led to widespread applications.
SPIE Maiman Laser Award: Bill Krupke
In recognition of his scientific, technical and community leadership, innovation, and numerous seminal results in laser science and technology.
SPIE Early Career Achievement Award — Academic Focus: Bhavin Shastri
In recognition of his pioneering efforts in the field of neuromorphic photonics and his contributions to interdisciplinary research across nanophotonics, unconventional computing, and silicon photonics that pushed the frontiers of machine learning.
SPIE Early Career Achievement Award — Industry/Government Focus: Lionel Clermont
In recognition of his significant achievements in the field of stray light control, particularly his work on the development of the ultrafast time-of-flight imaging characterization method.
SPIE Maria J. Yzuel Educator Award: Rajpal Sirohi
In recognition of his many years of service in the field of optics through leadership, capacity building, and outreach.
SPIE Aden and Marjorie Meinel Technology Achievement Award: Ge Wang
In recognition of his pioneering contributions in X-ray and optical molecular tomography, including their coupling for biomedical applications.
The complete listing of all SPIE awards and recipients is available here .
About SPIE
SPIE, the international society for optics and photonics, brings engineers, scientists, students, and business professionals together to advance light-based science and technology. The Society, founded in 1955, connects and engages with our global constituency through industry-leading conferences and exhibitions; publications of conference proceedings, books, and journals in the SPIE Digital Library; and career-building opportunities. Over the past five years, SPIE has contributed more than $22 million to the international optics community through our advocacy and support, including scholarships, educational resources, travel grants, endowed gifts, and public-policy development. www.spie.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220110005942/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom